Am J Transplant, Volume 16, Suppl 3 Archives - Page 26 of 180 - ATC Abstracts

2016 American Transplant Congress
Long-Term Follow-Up of Renal Transplant Recipients (RTR) Treated with IVIG for De Novo Donor Specific Antibodies (DSA).
R. Knight,¹ S. Patel,¹ J. Loucks-DeVos,² S. Kuten,¹ A. Gaber.¹
¹Houston Methodist Hospital, Houston, TX; ²Kansas University Medical Center, Kansas City, KS.
Intravenous immune globulin (IVIG) may be beneﬁcial for pre-emptive treatment of de novo DSA in RTR without biopsy-proven acute rejection (AR). Herein, we present long-term…
2016 American Transplant Congress
Is Ketorolac Really Safe for Donor Nephrectomy?
K. Takahashi, K. Putchakayala, L. Malinzak, J. Denny, M. Abouljoud, D. Kim.
Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI.
Background. Ketorolac is a nonsteroidal anti-inflammatory drug used for postoperative pain management. The purpose of this study is to assess the impact of ketorolac after…
2016 American Transplant Congress
Clinical Outcome on Kidney Retransplantation in Comparison with First Kidney Transplantation in Korea – Nationwide Cohort Study.
J. Kim,^1,2 T. Ban,^1,2 B. Jung,^1,2 B. Choi,^1,2 C. Park,^1,2 C. Yang,^1,2 Y.-S. Kim.^1,2
¹Transplantation Research Center, Seoul St. Mary's Hospital, Seoul, Republic of Korea; ²Internal Medicine, Seoul St. Mary's Hospital, Seoul, Republic of Korea.
Due to the limitation of the survival of kidney allograft, increasing number of patients need to take re-transplantation (re-KT) after the first allograft failure. In…
2016 American Transplant Congress
Urinary Markers of Proximal Tubular Dysfunction in Kidney Transplant as Predictors for CKD.
P. Garcia, V. Garcia-Nieto, J. Navarro, E. Martin, A. Rivero, A. Jarque, J. Gonzalez-Posadas, M. Macia.
Nephrology, Universitary NTRA.SRA.Candelaria Hospital, SC Tenerife, Spain.
AIMS:Analyze urinary markers of proximal tubular dysfunction (PTD)(b2 microglobulin (b2m),N-acetyl-glucosaminidase (NAG) and Clara Cell Protein (CC16)) in kidney transplant (KT) patients, compared with a healthy…
2016 American Transplant Congress
Living Related Small Bowel Transplantation in Children, a Single-Center Experience – Growth, Development and Quality of Life 10 Years After Transplant.
S. Garcia Aroz,¹ I. Tzvetanov,¹ E. Hetterman,² J. Hoonbae,¹ M. Spaggiari,¹ J. Oberholzer,¹ G. Testa,³ E. John,⁴ E. Benedetti.¹
¹Surgery, University of Illinois, Chicago, IL; ²Pharmacy, University of Illinois, Chivago, IL; ³Surgery, Baylor Medical Center, Dallas, TX; ⁴Pediatrics, University of Illinois, Chicago, IL.
Summary Background: Pediatric patients with irreversible intestinal failure present multiple challenges due to their young ages and their associated growth needs. We have previously published…
2016 American Transplant Congress
Distinct Effects of Chronic Hyperglycemia on Cellular and Humoral Alloresponses In Vivo.
N. Bishop,¹ K. Beard,² R. Gill.²
¹Immunology and Microbiology, University of Colorado Denver, Aurora, CO; ²Surgery, University of Colorado Denver, Aurora, CO; ³Surgery, University of Colorado Denver, Aurora, CO.
Background: Diabetes constitutes a significant problem in the transplant recipient. Diabetes is associated with impaired immunity to pathogens but its effect on alloimmunity remains ambiguous.…
2016 American Transplant Congress
Anti-BTLA Antibody (6B2) Induced Prolongation of Fully MHC-Mismatched Murine Cardiac Allograft and Generation of Foxp3+ Regulatory T Cells.
M. Uchiyama,^1,2 E. Yin,^2,3 X. Jin,^2,4 T. Shimokawa,¹ H. Yagita,⁵ M. Niimi.²
¹Cardiovascular Surgery, Teikyo University, Tokyo, Japan; ²Surgery, Teikyo University, Tokyo, Japan; ³Cardiovascular Surgery, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China; ⁴Thoracic Surgery, The 3rd Affiliated Hospital of Harbin Medical University, Harbin, China; ⁵Immunology, Juntendo University Hospital, Tokyo, Japan.
Background: The co-inhibitory receptor B and T lymphocyte attenuator (BTLA; CD272) has been implicated in the regulation of autoimmune and may potentially play an important…
2016 American Transplant Congress
Successful Human-to-NonHuman Primate Pancreatic Islet Intraportal Xenotransplantation Using a Human Allo-Based Immunosuppression Regimen and Its Potential Pre-Clinical Application.
J. McGarrigle,¹ M. Bochenek,¹ E. Marchese,¹ A. Khan,¹ D. Gutierrez,^1,2 A. Mikalauskaite,¹ B. McCracken,¹ M. Reedy,¹ M. Omami,¹ C.-C. Yeh,¹ M. Spaggiari,¹ M. Nourmohammadzadeh,^1,2 D. Isa,¹ S. Ghani,¹ L.-J. Wang,¹ J. Mendoza-Elias,^1,2 Y. Wang,¹ J. Oberholzer.^1,2
¹Surgery, University of Illinois at Chicago, Chicago; ²Bioengineering, University of Illinois at Chicago, Chicago.
Intraportal pancreatic islet cell transplantation is a successful treatment for type-1 diabetes (T1DM) in humans. Unfortunately, the lack of donor pancreatic organs is a major…
2016 American Transplant Congress
Culture Specific Interventions to Increase Organ Donation Advocacy in a Hispanic Serving Institution.
Y. Tasnif,¹ S. Ghaddar,² S. Saladin,³ A. Alaniz.¹
¹Cooperative Pharmacy Program, University of Texas - Rio Grande Valley, Edinburg, TX; ²South Texas Border Health Disparities Center, University of Texas - Rio Grande Valley, Edinburg, TX; ³School of Rehabilitation Services and Counseling, University of Texas - Rio Grande Valley, Edinburg, TX.
Organ donation rates among Hispanics are lower relative to non-Hispanic whites. The purpose of this study is to assess whether participation in a culture-specific educational…
2016 American Transplant Congress
Socioeconomic Status and Readmission Following Kidney Transplant.
S. DiBrito, E. King, M. O'Hare, D. Segev.
Transplant Surgery, Johns Hopkins Hospital, Baltimore.
Our group has previously demonstrated that 31% of kidney transplant recipients are readmitted within 30 days of discharge from the original hospitalization. Patient-level contributors such…